Viking Therapeutics' Chairman joins Dechra Pharmaceuticals' board

Dr Lawson Macartney Image: Inserm Transfer Initiative’

Dechra has appointed Lawson Macartney to the Board as Non-Executive Director with effect from December 1, 2016. 

Dr Macartney, a qualified veterinarian, is Chairman of Viking Therapeutics Inc., a developer of novel therapeutics for patients suffering from metabolic and endocrine disorders, and an adviser to several biopharmaceutical companies and life science consultancies.  Prior to this, Dr Macartney was President and CEO of Ambrx Inc., Senior Vice President and Head of Emerging Business at Shire AG, and held various senior, global commercial, sales, marketing and strategy roles at GlaxoSmithKline plc.

Ian Page, Chief Executive Officer, Dechra Pharmaceuticals said:

“We are delighted to welcome Lawson to the Board and we look forward to working with him.  Lawson’s 30 years of experience gained in the global pharmaceutical industry will bring further knowledge and expertise of product development to the Board.”